Neuraptive Therapeutics
PrivateLast Round
Series B
Oct 14, 2022
Est. Valuation
$149.5M
Total Funding Raised
$32M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Neuraptive Therapeutics operates in Healthcare & Life Sciences and is based in Chesterbrook, Pennsylvania. Its latest recorded funding round was a Series B round in October 2022.
Neuraptive Therapeutics is a biotechnology company that develops novel therapeutics and medical products to improve outcomes for peripheral nerve injuries.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neuraptive Therapeutics Comparables
Compare Neuraptive Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioCircuit Technologies | 82% | |
| Regenity Biosciences | 79% | |
| Axogen Inc | 79% |
For institutional investors. Book with your work email.
Neuraptive Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 14, 2022 | ||||
| Series A | Dec 19, 2018 | ||||
| Seed | Sep 6, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neuraptive Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Benjamin Franklin Technology Partners | Series A |
| New Rhein Healthcare Investors | Series A |
| Central Texas Angel Network | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 42% MoM.
- May 18, 2026
Monthly visitors increased 99% MoM to 1.7K.
For institutional investors. Book with your work email.
Neuraptive Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neuraptive Therapeutics's valuation, stock price, and market status.
Is Neuraptive Therapeutics a public or private company?
Neuraptive Therapeutics is a private company.
What is the current stock price of Neuraptive Therapeutics?
Neuraptive Therapeutics is a private company, so its shares have no public market price. Caplight tracks Neuraptive Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neuraptive Therapeutics worth (valuation)?
Neuraptive Therapeutics's valuation is estimated at $149.5M based on funding round data.
Can I buy Neuraptive Therapeutics stock?
Neuraptive Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neuraptive Therapeutics's last funding round?
Neuraptive Therapeutics's most recent funding round was Series B on October 14, 2022.
Who are the main investors in Neuraptive Therapeutics?
Key investors in Neuraptive Therapeutics include New Rhein Healthcare Investors.
Will Neuraptive Therapeutics IPO soon?
No public IPO plans have been announced for Neuraptive Therapeutics.
How can I track Neuraptive Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Neuraptive Therapeutics's shares on secondary markets.